arrow_back Back to App

Easier Biosimilar Approval: Fewer Studies, Faster Access.

This act aims to simplify the approval process for biosimilar drugs, which are more affordable alternatives to expensive biological medicines. This could lead to citizens gaining faster access to necessary treatments and potentially lower healthcare costs, as fewer studies will be required to bring these drugs to market.
Key points
Fewer required studies: The act eliminates the need for certain studies assessing the risks of alternating or switching between biosimilar and reference products.
Faster drug access: Streamlined procedures may accelerate the availability of more affordable alternatives, increasing treatment accessibility.
Potential savings: Increased competition and faster introduction of biosimilars could lead to lower treatment costs for patients and the healthcare system.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_6
Sponsor: Sen. Lee, Mike [R-UT]
Process start date: 2022-11-17
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Biosimilar Red Tape Elimination Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_6.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-11-17.

What are the main provisions?

Key points include:

  • Fewer required studies: The act eliminates the need for certain studies assessing the risks of alternating or switching between biosimilar and reference products.
  • Faster drug access: Streamlined procedures may accelerate the availability of more affordable alternatives, increasing treatment accessibility.
  • Potential savings: Increased competition and faster introduction of biosimilars could lead to lower treatment costs for patients and the healthcare system.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Lee, Mike [R-UT].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health